Stocks / NASDAQ / Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

Our Opinion

Fate Therapeutics, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.

Supporting Evidence:

The company stated in the following report that they conduct preclinical trials of their drugs on animals.

“During the second quarter of 2013, we completed in vitro and animal studies demonstrating that the clinical potency and efficacy profile of ProHema may be significantly improved by programming the biological properties of CD34+ cells and T cells of umbilical cord blood in a nutrient-rich processing media.” (Page 11) Read the full document.

Company Description

Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. The company products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. Fate Therapeutics was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. [Source: MarketWatch]

Company Website: